RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Orchard Therapeutics Stock

Orchard Therapeutics Equity 2024

Orchard Therapeutics Equity

98.3 M USD

Ticker

ORTX

ISIN

US68570P1012

WKN

A2N8KD

In 2024, Orchard Therapeutics's equity was 98.3 M USD, a -53.19% increase from the 210 M USD equity in the previous year.

Orchard Therapeutics Aktienanalyse

What does Orchard Therapeutics do?

Orchard Therapeutics PLC is a biopharmaceutical company based in London. It was founded in 2015 and is traded on the NASDAQ and the London Stock Exchange. The company focuses on the development and commercialization of gene therapy products for rare and life-threatening diseases for which there is currently no cure. Orchard Therapeutics has its roots in the research and development of gene therapy products at the University College London (UCL) and the Great Ormond Street Hospital for Children (GOSH). The company has a strong partnership with these institutions and utilizes their resources for the development of new therapies. This close collaboration allows Orchard Therapeutics to focus on the research and development of gene therapy products for rare diseases. The business model of Orchard Therapeutics is to develop gene therapies for rare diseases that currently have no treatment options. These products are then licensed to pharmaceutical companies that are responsible for the production and marketing of the products. Orchard Therapeutics then receives a licensing fee and potential milestone payments for the sale of the products. Orchard Therapeutics has various divisions specializing in the development of gene therapies for different diseases. For example, the hemophilia division develops gene therapies for people with hemophilia, a genetic disease that impairs blood clotting. Other divisions focus on the development of gene therapies for muscular dystrophy, B-cell immunodeficiency, and chronic granulomatosis. The company has a broad portfolio of products currently in development. One of the most well-known products is "OTL-101," a gene therapy for the treatment of adenosine deaminase deficiency immunodeficiency (ADA-SCID), a severe type of immunodeficiency that can lead to infections and serious illness. Another important gene therapy is "OTL-103," which is used for the treatment of Wiskott-Aldrich syndrome (WAS), a rare genetic disorder that affects the immune system. Orchard Therapeutics manages to develop gene therapies for rare diseases by using a unique technology platform. This platform includes the use of lentiviruses that can insert genetic information into cells of the body. The gene therapies developed on this platform can help replace defective or missing genes with functional genes to treat diseases. Overall, Orchard Therapeutics is an emerging biotechnology company that focuses on the development of gene therapy products for rare and life-threatening diseases. The company has a strong partnership with leading medical institutions and utilizes a unique technology platform to develop gene therapies. With a wide range of products in development and potential groundbreaking therapies in the pipeline, Orchard Therapeutics is expected to play a significant role in the development of gene therapies for rare diseases. Orchard Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Orchard Therapeutics's Equity

Orchard Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Orchard Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Orchard Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Orchard Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Orchard Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Orchard Therapeutics stock

What is the equity of Orchard Therapeutics this year?

Orchard Therapeutics has equity of 98.3 M USD this year.

What was the equity of Orchard Therapeutics compared to the previous year?

The equity of Orchard Therapeutics has increased/decreased by -53.19% decreased compared to the previous year.

What impact does a high equity have on investors of Orchard Therapeutics?

A high equity is advantageous for investors of Orchard Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Orchard Therapeutics?

A low equity can be a risk for investors of Orchard Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Orchard Therapeutics affect the company?

An increase in equity of Orchard Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Orchard Therapeutics affect the company?

A reduction in equity of Orchard Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Orchard Therapeutics?

Some factors that can affect the equity of Orchard Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Orchard Therapeutics so important for investors?

The equity of Orchard Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Orchard Therapeutics take to change the equity?

To change equity, Orchard Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Orchard Therapeutics pay?

Over the past 12 months, Orchard Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orchard Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Orchard Therapeutics?

The current dividend yield of Orchard Therapeutics is .

When does Orchard Therapeutics pay dividends?

Orchard Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orchard Therapeutics?

Orchard Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Orchard Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orchard Therapeutics located?

Orchard Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orchard Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orchard Therapeutics from 11/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Orchard Therapeutics pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of Orchard Therapeutics in the year 2023?

In the year 2023, Orchard Therapeutics distributed 0 USD as dividends.

In which currency does Orchard Therapeutics pay out the dividend?

The dividends of Orchard Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Orchard Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Orchard Therapeutics

Our stock analysis for Orchard Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orchard Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.